Columbia, Maryland, January 8, 2018 – WellDoc®, a leading digital health company, announced that two executives will present at key digital health conferences this week. President and CEO Kevin McRaith will give a corporate overview at the 2018 Digital Medicine and Medtech Showcase at Parc 55 in San Francisco on January 9, at 11:30 a.m. PST. In addition, Chief Strategy Officer Anand Iyer, Ph.D., will give the keynote address, “Hitting the Sweet Spot with AI and Machine Learning: A Diabetes Revolution” at the 9th Annual Digital Health Summit at the 2018 Consumer Electronics Show (CES) at the Venetian in Las Vegas on January 10 at 1:00 p.m. PST.
The Digital Medicine and Medtech Showcase highlights the digital health and medical device sector with company presentations, networking events and partnering meetings. It is an annual event that takes place during the same timeframe as J.P. Morgan’s 36th Annual Healthcare Conference and Biotechnology Innovation Organization’s (BIO) One on One Partnering™ events.
The Digital Health Summit is a conference that focuses on the fast-growing sector of the healthcare industry and the prospects and issues facing businesses, entrepreneurs, clinicians, researchers and patients. The conference is part of the CES, an annual trade-only event organized by the Consumer Electronics Association to showcase consumer technologies and its innovations.
WellDoc® is a leading digital health company revolutionizing chronic disease management to help transform lives. Our groundbreaking technology is guiding individuals through the complicated journey of living with chronic diseases, with a goal of improving their health and helping them to be more balanced. We are the first digital health company based on a life science business model with a foundation that is built on randomized clinical trials that demonstrate significant clinical outcomes. We have mastered diabetes management by taking an aggressive and innovative approach that utilizes sophisticated logic and precise algorithms, and integrates the most advanced mobile technology, behavioral insight, and diabetes education for those living with type 2 diabetes.
Our FDA-cleared, proven digital therapeutic, BlueStar®, provides real-time and timely individualized coaching and support, as well as diabetes educational tools that are actionable and personal. Our clinical evidence shows a 1.7 to 2.0-point mean A1C reduction for adults living with type 2 diabetes who used BlueStar®. In November 2017, the IQVIA Institute for Human Data Science (formerly Quintiles/IMS) named BlueStar the “top app” in clinical diabetes treatment. For more information, visit www.welldoc.com.